$18.14 0.00% ($0.00)
  • 1D
  • 1W
  • 1M
  • 1Y
  • 5Y
  • YTD

Get ready to invest


About Vaxcyte

Vaxcyte Inc. is a vaccine company. The Company is focused on developing vaccines designed to prevent or treat common and deadly infectious diseases worldwide. Its cell-free protein synthesis platform enables it to design and produce protein carriers and antigens. Its pipeline includes pneumococcal conjugate vaccine (PCV) candidates. Its lead vaccine candidate is VAX-24, a 24-valent investigational PCV. Its pipeline also includes VAX-XP, VAX-A1 and VAX-PG. The Company's second PCV, VAX-XP, uses its modular platform and builds on the technical proof of concept established by VAX-24. VAX-A1 is a conjugate vaccine being developed for group A strep infections. VAX-PG is being developed as a protein vaccine for the treatment of periodontitis.

Stock Analysis

last close $19.43
1-mo return -9.9%
3-mo return -21.7%
avg daily vol. 351.91T
52-week high 29.29
52-week low 15.51
market cap. $1.0B
forward pe -
annual div. -
roe -27.5%
ltg forecast -
dividend yield -
annual rev. $--
inst own. 88.6%

Subscribe now for daily local and international financial news